Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib With CCRT and Consolidation Tislelizumab in Locally Advanced NSCLC
NCT05481775Phase 2Withdrawn
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2022
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Planned start Apr 2022; status: withdrawn.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05481775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05481775.